Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 555 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombosis, Venous Clear all
Completed Phase 1 Interventional Results available

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

NCT00412464
View directory record Official record
Conditions
Thrombosis, Heparin-induced Thrombocytopenia
Interventions
Fondaparinux
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439
View directory record Official record
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

NCT02070237
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section, Venous Thromboembolism, Postpartum Deep Phlebothrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

NCT00720915
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 25, 2026, 7:00 AM EDT
Completed No phase listed Observational

Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty

NCT01984190
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Little Rock, Alaska • La Jolla, California • Menlo Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated No phase listed Observational

Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein Thrombosis (DVT)

NCT01045759
View directory record Official record
Conditions
DEEP VEIN THROMBOSIS
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

NCT00041782
View directory record Official record
Conditions
Neoplasms, Deep Vein Thrombosis
Interventions
Dalteparin (Fragmin)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

NCT02412982
View directory record Official record
Conditions
Traumatic Injury, Venous Thromboembolism
Interventions
Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Sickle Cell Trait and the Risk of Venous Thromboembolism

NCT01148940
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Semuloparin sodium, Placebo (for semuloparin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Enoxaparin Metabolism in Reconstructive Surgery Patients

NCT02411292
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 25, 2026, 7:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome

NCT00395265
View directory record Official record
Conditions
Venous Thrombosis, Venous Insufficiency
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
40 Years to 79 Years
Enrollment
2,211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Not applicable Interventional

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
MSK-ACCESS, ctDNA/VTE Risk Score:
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

NCT00211471
View directory record Official record
Conditions
Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
8,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
82
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 25, 2026, 7:00 AM EDT
Not listed Phase 3 Interventional

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

NCT02486666
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 25, 2026, 7:00 AM EDT
Suspended Not applicable Interventional

CLEANer Aspiration for Pulmonary Embolism

NCT06189313
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Interventions
Cleaner Pro Thrombectomy System
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

NCT04354155
View directory record Official record
Conditions
Infection Viral, Thromboses, Venous, COVID-19
Interventions
Enoxaparin Prefilled Syringe [Lovenox]
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 25, 2026, 7:00 AM EDT